NYSE$AMN
AMN Healthcare Services Inc. · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
AMN Healthcare Services, Inc. reported its fourth quarter and full year 2024 financial results, with quarterly revenue of $735 million and a GAAP loss of ($4.90) per share.
AMN Healthcare Services, Inc. exceeded expectations in Q4 2024, driven by better labor disruption and core nurse and allied staffing revenue. The company reported a net loss due to a non-cash goodwill impairment, but saw strong cash flow from operations and reduced debt.
- Fourth quarter 2024 financial results surpassed expectations due to stronger labor disruption and core nurse and allied staffing revenue.
- The company recorded a net loss of ($187.5 million) in Q4 2024, primarily due to a $222 million non-cash goodwill impairment charge.
- Cash flow from operations was robust at $73 million for the quarter and $320 million for the full year.
- AMN Healthcare successfully reduced its debt by $75 million in the quarter, contributing to a full-year repayment of $250 million.
Headline financials
Revenue & EPS history
AMN Healthcare · Revenue · Quarterly
$735M
Revenue by segment
AMN Healthcare · $748M total across 3 segments · Q4 2025
- Nurse & Allied Solutions$491M—65.6%
- Physician & Leadership$170M—22.7%
- Technology & Workforce$88M—11.8%
Forward guidance
For the first quarter of 2025, consolidated revenue is projected to be between $660 million and $680 million, representing a 17-20% decrease year-over-year. This outlook includes an assumption of $24 million in labor disruption revenue.
Tailwinds
- Guidance assumes $24 million of labor disruption revenue, indicating continued demand in this area.
- The company expects to maintain positive adjusted EBITDA margin between 7.7% and 8.2%.
- The ShiftWise Flex VMS platform onboarding was completed ahead of schedule, which could improve efficiency.
- Strategic accounts showed net positive client retention for the full year 2024.
- MSP business in locum tenens rebounded with over 20% volume increase in H2 2024.
Headwinds
- Consolidated revenue is projected to decrease by 17-20% year-over-year in Q1 2025.
- Nurse and Allied Solutions segment revenue is expected to be 22-25% lower than prior year.
- Physician and Leadership Solutions segment revenue is projected to be 9-11% lower year-over-year.
- Technology and Workforce Solutions segment revenue is projected to be down 8-10% year-over-year.
- Operating margin is projected to be negative, ranging from (0.3)% to 0.4%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.0%
Avg return
Earnings day
-1.9%
Avg return
5 days after
-0.6%
Avg return
30 days after
52%
34 / 66 earnings
Positive
+29.2%
Q1 2026
Best reaction
-29.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +29.2% | +38.5% | +41.5% | |
| Q4 2025 | +11.4% | +15.8% | +4.2% | |
| Q3 2025 | -3.4% | -10.0% | -11.8% | |
| Q2 2025 | +2.3% | +10.2% | +23.2% | |
| Q1 2025 | +8.2% | +7.1% | +3.8% | |
| Q4 2024 | +6.7% | +0.5% | -6.8% | |
| Q3 2024 | -29.5% | -36.7% | -36.2% | |
| Q2 2024 | -3.1% | -11.9% | -24.0% | |
| Q1 2024 | -9.3% | +3.4% | -10.1% | |
| Q4 2023 | -20.9% | -25.5% | -24.7% | |
| Q3 2023 | -12.2% | -17.7% | -9.5% | |
| Q2 2023 | -16.4% | -16.6% | -18.6% | |
| Q1 2023 | +7.7% | +10.3% | +18.0% | |
| Q4 2022 | -4.0% | -2.3% | -13.4% | |
| Q3 2022 | -7.5% | -0.4% | +1.7% | |
| Q2 2022 | +1.8% | -1.7% | -12.7% | |
| Q1 2022 | -8.2% | -10.6% | -1.3% | |
| Q4 2021 | +8.8% | +5.3% | +10.4% | |
| Q3 2021 | -8.2% | -1.4% | +3.7% | |
| Q2 2021 | +5.4% | +3.8% | +15.4% | |
| Q1 2021 | +7.6% | +10.3% | +11.0% | |
| Q4 2020 | +4.1% | -0.7% | +1.4% | |
| Q3 2020 | -5.8% | -7.0% | -1.9% | |
| Q2 2020 | +4.8% | -4.5% | -1.7% | |
| Q1 2020 | -9.3% | -12.1% | +13.0% | |
| Q4 2019 | +9.6% | +5.6% | +4.0% | |
| Q3 2019 | -0.5% | +2.1% | +0.8% | |
| Q2 2019 | +7.7% | +11.4% | +15.5% | |
| Q1 2019 | +1.9% | -0.4% | -6.0% | |
| Q4 2018 | -12.5% | -14.7% | -26.7% | |
| Q3 2018 | +13.3% | +11.6% | +23.9% | |
| Q2 2018 | -15.2% | -10.4% | -5.4% | |
| Q1 2018 | -21.9% | -21.6% | -14.6% | |
| Q4 2017 | +4.8% | +4.8% | +10.9% | |
| Q3 2017 | -3.6% | -1.6% | +16.3% | |
| Q2 2017 | +1.1% | +6.9% | +4.4% | |
| Q1 2017 | -6.8% | -6.2% | -9.0% | |
| Q4 2016 | +4.0% | +7.9% | +10.3% | |
| Q3 2016 | -1.6% | -2.7% | -7.8% | |
| Q2 2016 | -11.9% | -13.8% | -13.5% | |
| Q1 2016 | +1.0% | — | — | |
| Q4 2015 | +1.8% | — | — | |
| Q3 2015 | +5.9% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q3 2014 | -1.7% | — | — | |
| Q2 2014 | +5.7% | — | — | |
| Q1 2014 | +3.8% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q4 2012 | +13.4% | — | — | |
| Q3 2013 | +13.4% | — | — | |
| Q2 2013 | +6.1% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q3 2012 | +4.0% | — | — | |
| Q2 2012 | +5.5% | — | — | |
| Q1 2011 | +19.4% | — | — | |
| Q1 2012 | +6.1% | — | — | |
| Q4 2011 | -2.0% | — | — | |
| Q4 2009 | -2.0% | — | — | |
| Q3 2011 | -3.7% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q1 2010 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro